Condition
Relapsed Refractory Multiple Myeloma clinical trials and research
As of November 12, 2026, Find a Trial lists 4 Relapsed Refractory Multiple Myeloma clinical trials that are recruiting, at sites in 15 countries (most in China (3), United States (2), Australia (1)). By phase: Phase 3 (1), Early Phase 1 (1), Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 15Countries
Newest Relapsed Refractory Multiple Myeloma clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| AZD0120 dual-target CAR-T (BCMA and CD19) versus standard treatments for relapsed refractory multiple myeloma | Phase 3 | Gilbert, Arizona and 142 other locations | Recruiting | Feb 6, 2026 |
| Elranatamab plus under-the-skin isatuximab for relapsed/refractory multiple myeloma | Phase 2 | Boston, Massachusetts and 2 other locations | Recruiting | Feb 18, 2025 |
| Treatment of relapsed/refractory multiple myeloma with ESO-T01 | Early Phase 1 | Wuhan, Hubei | Recruiting | Jan 24, 2025 |
| New CAR-T therapy with IL-15 for treating blood cancers | — | Taiyuan, Shanxi | Recruiting | Jan 20, 2025 |
All recruiting trials (4)
-
AZD0120 dual-target CAR-T (BCMA and CD19) versus standard treatments for relapsed refractory multiple myeloma
This trial tests whether a dual-target CAR-T therapy called AZD0120 works better than commonly used drug regimens for adults with relapsed or refractory multiple myeloma.
-
Elranatamab plus under-the-skin isatuximab for relapsed/refractory multiple myeloma
This trial will test whether combining elranatamab with subcutaneous isatuximab helps people with relapsed or refractory multiple myeloma who have had at least two prior therapies.
-
Treatment of relapsed/refractory multiple myeloma with ESO-T01
This study is testing a new CAR T-cell therapy called ESO-T01 to see if it can help people with relapsed or refractory multiple myeloma feel better.
-
New CAR-T therapy with IL-15 for treating blood cancers
This study is testing a new CAR-T therapy combined with IL-15 to see if it can help people with blood cancers like leukemia and multiple myeloma.
Related topics
Quick answers
How many Relapsed Refractory Multiple Myeloma clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 15 countries. The most sites are in China (3 trials), United States (2 trials), Australia (1 trial), Brazil (1 trial), Canada (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 3: 1, Early Phase 1: 1, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.